Abuse resistant oxycodone immediate release - Inspirion Delivery Sciences

Drug Profile

Abuse resistant oxycodone immediate release - Inspirion Delivery Sciences

Alternative Names: Oxycodone hydrochloride tablets; RoxyBond

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inspirion Delivery Sciences
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Pain
  • Clinical Phase Unknown Drug abuse

Most Recent Events

  • 12 Apr 2018 Daiichi Sankyo expects launch of abuse resistant oxycodone immediate release in 2018
  • 15 Jan 2018 RoxyBond™ is not yet launched for Pain in USA (PO) (Literature review)
  • 30 May 2017 RoxyBond™ licensed to Daiichi Sankyo in USA for commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top